Adar1 Capital Management, Llc Acquires 800 Shares of Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock in a transaction that occurred on Tuesday, May 12th. The stock was acquired at an average cost of $13.83 per share, with a total value of $11,064.00. Following the transaction, the insider owned 830,584 shares in the company, valued at $11,486,976.72. This trade represents a 0.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was acquired at an average cost of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Stock Performance

RLYB traded up $0.32 during mid-day trading on Wednesday, reaching $14.35. 150,607 shares of the stock were exchanged, compared to its average volume of 633,223. Rallybio Corporation has a 1 year low of $2.16 and a 1 year high of $15.31. The stock has a market capitalization of $75.91 million, a PE ratio of -5.61 and a beta of -1.10. The company has a 50 day moving average price of $9.70 and a two-hundred day moving average price of $6.93.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.23 million.

Wall Street Analysts Forecast Growth

RLYB has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Rallybio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.